Cynata Therapeutics Limited Stock Today
| CYYNF Stock | USD 0.14 0.00 0.00% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Cynata Therapeutics is trading at 0.14 as of the 26th of February 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.14. Cynata Therapeutics has more than 66 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of January 2025 and ending today, the 26th of February 2025. Click here to learn more.
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. The company has 143.28 M outstanding shares. More on Cynata Therapeutics Limited
Moving together with Cynata Pink Sheet
| 0.76 | NVO | Novo Nordisk AS | PairCorr |
| 0.76 | NONOF | Novo Nordisk AS | PairCorr |
| 0.74 | CSLLY | CSL | PairCorr |
| 0.73 | REGN | Regeneron Pharmaceuticals | PairCorr |
Moving against Cynata Pink Sheet
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Cynata Pink Sheet Highlights
| CEO | Ross Macdonald |
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Cynata Therapeutics Limited [CYYNF] is a Pink Sheet which is traded between brokers over the counter. The company currently falls under 'Micro-Cap' category with a current market capitalization of 35.82 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Cynata Therapeutics's market, we take the total number of its shares issued and multiply it by Cynata Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Cynata Therapeutics classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 143.28 M outstanding shares.
Cynata Therapeutics Limited has accumulated about 26.79 M in cash with (3.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cynata Therapeutics Probability Of Bankruptcy
Ownership AllocationCynata Therapeutics holds a total of 143.28 Million outstanding shares. Cynata Therapeutics Limited shows 14.77 percent of its outstanding shares held by insiders and 24.8 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cynata Ownership Details
Cynata Therapeutics Risk Profiles
| Mean Deviation | 0.7854 | |||
| Standard Deviation | 3.24 | |||
| Variance | 10.49 | |||
| Risk Adjusted Performance | (0.08) |
Cynata Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Cynata Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.